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Abstract 2-Quinolone analogs are powerful inhibitors of farnesyl transferase, and are a novel class
of anticancer drugs. The present study focused on continual efforts to elucidate the anticancer activ-
ity of synthesized 2-quinolone derivatives without N-methyl or 3-aryl substitution. Three derivatives
namely JST, JST2 and JST13 were synthesized in our lab and screened for in vitro and in vivo anti-
cancer activities. Signiﬁcant cytotoxicity was observed in MCF-7 cells treated with JST2 and JST13.
Both the derivatives’ treatment showed damage to the DNA. In vivo studies for JST2 and JST13
were performed at two doses 100 and 200 mg/kg using Ehrlich ascites carcinoma (liquid) and
Dalton lymphoma ascites (solid) models. Both derivatives showed a signiﬁcant reduction in the
tumor progression by increasing the mean life span and by improving the haematological proﬁle
and antioxidant status of the liver in a liquid tumor model. More prominent effect was observed
in a solid tumor model by reduction in solid tumor weight and tumor volume.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
1. Introduction
Cancer has the second highest mortality rate after cardiovascu-
lar diseases throughout the world. Even though remarkable
progress has been made by medical science, the availability
of safe and speciﬁc anticancer drugs has remained a major
challenge in clinical practice. Development of tumor resistance
against available treatment modes like radiotherapy, chemo-
therapy together with patient noncompliance raises the de-
mands for the introduction of newer drugs in cancer
management. Hence, ﬁnding a reliable molecule for cancer
treatment remained the prime aim of research scientists. Con-
sidering all these points, a number of natural and synthetic
molecules/compounds have been studied for cancer drug
Abbreviations: DLA, Dalton lymphoma ascites; EAC, Ehrlich ascites
carcinoma; JST, 7-Amino-4-methylquinoline-2(1H)-one; JST2, N(1H)-
7-(20-chloro benzoylamino)-4-methyl quinoline-2-(1H)-one; JST13,
N(1H)-7-(10-napthoyl benzoylamino)-4-methyl quinoline-2-(1H)-one);
IMLS, Increase in mean life span; MST, Mean survival time.
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discovery and some of them were found promising. Among
synthetic molecules, 2-quinolone and its derivatives have
emerged as one of the promising lead molecules in cancer treat-
ment. Besides its anticancer activity, 2-quinolone also has been
reported to possess antimalarial, antiprotozoal activity
(Anquetin et al., 2006), antibacterial (Kulkarni et al., 1991),
antiviral (Dodia and Shah, 2001), antihypertensive, 5-HT
antagonistic, cardiotonic (Leclerc et al., 1986), diuretic, and
anti-inﬂammatory activities (Kulkarni et al., 1990).
A few studies demonstrated the participation of 2-quino-
lones in the regulation of signal transduction, cell growth
and apoptosis (Chen et al., 2007) as a novel class of anti-cancer
agents (Brunner et al., 2003) which act by inhibiting the far-
nesyl transferase enzyme. These derivatives of 2-quinolone
were found to be having either 3-aryl and N-methyl substitu-
tion (Joseph et al., 2002) or 3,4,6-substitution (Wall et al.,
2008). Tipifarnib, a 3-aryl-2-quinolone derivative acts by
inhibiting the farnesyl transferase enzyme and is currently un-
der clinical trial. Assuming that 2-quinolone analogs are pow-
erful inhibitors of farnesyl transferase (Li et al., 2005), a series
of compounds without N-methyl or 3-aryl substitution have
been synthesized in our lab and explored for anticancer activ-
ity (Kumar et al., 2012). Those compounds were found to in-
duce apoptosis in MCF-7 cells through the Bax induced
pathway. In the present study we are continuing to elucidate
the anticancer activity of similar compounds synthesized in
our lab for their cellular cytotoxicity and DNA level toxicity
using human breast cancer cell line (MCF-7) and animal mod-
els of cancer (solid and liquid tumor models).
2. Materials and methods
2.1. Materials
Minimum essential media (MEM), MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) were
obtained from Sigma Chemicals Co., St. Lious, MO, USA
and DMSO from SD-ﬁne chemicals, Mumbai, India. Cisplatin
was obtained from Dabur Pharma Ltd., New Delhi (Chemo-
plat). Other chemicals were obtained from local reliable
vendors.
2.2. Test drugs preparation
All in vitro cytotoxic studies were performed using DMSO
(0.1%) as solvent. In control samples equimolar amount of
DMSO was maintained to rule out its cytotoxic effect. For
in vivo screening the test drugs were suspended in 2% gum aca-
cia immediately before use and given orally. The standard anti-
cancer drug (Cisplatin) was injected intraperitoneally.
2.3. Cell line and culture media
The Ehrlich Ascites Carcinoma (EAC), liquid tumor model
cells and Dalton Lymphoma Ascites (DLA), solid tumor mod-
el cells were obtained from Dr. Ramdasan Kuttan (Director,
the Amala Cancer Research Center, Amala Nagar, Thrissur,
Kerala, India) and were maintained and propagated by serial
intraperitoneal transplantation of the cells into an aseptic envi-
ronment. The cells propagated for 12–14 days were used in the
experiments. For in vitro cytotoxicity studies the human breast
adenocarcinoma cell line (MCF7) was used, procured from
National Centre for Cell Science, Pune, and maintained in
our tissue culture lab. Cells were routinely grown in the
25 cm2 culture ﬂasks with loosened caps containing minimum
essential medium (MEM) supplemented with 10 percent fetal
calf serum and 50 lg/ml gentamicin sulfate at 37C in an atmo-
sphere of 5% CO2 in humidiﬁed air in a CO2 incubator.
2.4. Animals
Animal care and handling was done as per the guidelines is-
sued by the CPCSEA (Committee for the Purpose of Control
and Supervision of Experiments on Animals), Govt. of India.
Prior permission was taken from the Institutional Animal Eth-
ics Committee for conducting the study (clearance certiﬁcate
No. IAEC-KMC/07/2007–2008). Eight to ten week old Swiss
albino mice weighing 26–30 g were selected from an inbred col-
ony maintained under controlled conditions of temperature
(23 ± 2 C), humidity (50 ± 5%) and light (14 and 10 h of
light and dark, respectively) at the Central Animal Research
Facility, Manipal University. Four animals were housed in
each polypropylene cage containing paddy husk as bedding.
The animals were provided with sterile food and water ad
libitum.
2.5. Test compounds
The test compounds used for the study were JST (7-amino 4-
methylquinolin-2(1H)-one), JST2 (N(1H)-7-(20-chloro ben-
zoylamino)-4-methyl quinoline-2-(1H)-one), and JST13
(N(1H)-7-(10-napthoyl benzoylamino)-4-methyl quinoline-2-
(1H)-one). These were synthesized and characterized in our
synthetic laboratory (Jayashree et al., 2010). The structures
are given in Fig. A.1.
3. Experimental pharmacology
3.1. In vitro cytotoxicity in human MCF-7 breast cancer cell line
A known number of cells (2 · 103 cells/well in 100 ll of med-
ium) were seeded in 96 well plates and incubated for 24 h for
the attachment of cells. Desired concentrations of test com-
pounds were prepared in 0.1% DMSO prior to the experiment.
The reactant mixtures were diluted with media and cells were
treated with different concentration ranges of the drug (1–
200 lM). After 72 h the media were removed and the cell cul-
tures were incubated with 100 ll MTT reagent (1 mg/ml) for
4 h at 37C, the formazan produced was then solubilized by
the addition of 100 ll DMSO. The suspension was placed on
a microvibrator for 5 min and then absorbance was recorded
at 540 nm by ELISA reader and then percentage cytotoxicity
was calculated (Francis and Rita, 1986).
3.2. DNA fragmentation studies
MCF-7, breast cancer cells (1 · 105 cells/ml) were seeded in
25 cm2 bottles and incubated for 24 h for the attachment of
cells. Desired concentrations of test compounds below the
CTC50 were exposed to the MCF-7 cells and incubated over-
night. The cells were lysed and DNA was extracted with diges-
tion buffer (pH 7.5) containing 0.5% SDS, 25 mM Tris–HCl,
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0.5% mg/ml proteinase K and 5 mM EDTA at 55 C over-
night. After extracting the cell lysates with phenol:choloro-
form:isoamyl alchol (25:24:1) and chloroform:isoamyl
alcohol (24:1), 3 M sodium acetate (pH 5.2) and absolute eth-
anol was added for the precipitation of DNA, and was washed,
dried and resuspended with Tris–EDTA buffer containing
RNase A (100 lg/ml) at 37C for 30 min. Approximately
10 lg of DNA was electrophoresed on a 1% agarose gel and
was visualized with ethidium bromide staining under UV light
(Raj et al., 2010).
3.3. Toxicological study [OECD-425]
Two compounds viz JST2 and JST13 that showed promising
results in the in vitro studies were subjected to toxicological
studies as per the OECD-425 guideline to obtain a safe dose
in mice.
3.4. In vivo cytotoxic activity in EAC inoculated mice (liquid
tumor model)
3.4.1. Effect on mean survival time (MST) and percentage
increase in mean life span (% IMLS) in EAC inoculated mice
The number of cells required to develop tumor in our labora-
tory animals were standardized. The desired EAC cells
(2.5 · 106 cells/mice) were injected intraperitoneally into each
mouse under aseptic conditions (Kviecinski et al., 2008). The
day of tumor inoculation was considered as zero day and ani-
mals were grouped randomly after 24 h of cell inoculation as
mentioned below.
Group 1 (2% acacia) animals in this group were treated
with 10 ml/kg 2% gum acacia by oral route.
Groups 2 and 3 (JST13) these groups of animals received
JST13 in the dose of 100 and 200 mg/kg, respectively by
oral route.
Groups 4 and 5(JST2) animals received JST2 100 and
200 mg/kg by the oral route.
Group 6 (cisplatin) animals were injected cisplatin (3.5 mg/
kg) by the i.p. route.
The doses of the test compound chosen were less than 1/
10th of the oral safe dose established in toxicity studies. The
drug treatment was started on day 1 and the test compounds
were administered p.o. on 1st, 3rd, 5th, 7th, 9th, 11th, and
13th days of tumor inoculation. The standard drug cisplatin
3.5 mg/kg, i.p. at a single dose was injected on day one. The
animals were monitored for 45 days and MST, % IMLS was
calculated. The MST was calculated by dividing the total num-
ber of days the animals survived to the total number of ani-
mals. The % IMLS time was calculated as follows,
[(MST in the treated group/MST in the control
group)  1] · 100. (Hazra et al., 2002).
3.4.2. In vivo cytotoxic activity on the hemotopoietic system in
EAC inoculated mice (n = 4)
The experimental design was the same as described above in
Section 3.4.1. A few drops of blood were withdrawn on day
14 from the retro orbital plexus of the animals. The blood sam-
ples were analyzed for total WBC and RBC count and hemo-
globin estimation (Brandao et al., 2008). Serum total protein
was determined by Cobas C-111 auto-analyzer using kits man-
ufactured by Roche Diagnostic Division.
3.4.3. Effect of test compounds on liver antioxidant enzymes in
EAC inoculated mice (n = 4)
Adopting the experimental design was the same as described
above in Section 3.4.1, animals were sacriﬁced by cervical dis-
location on day 14 and the livers were dissected out after trans-
cardial perfusion with ice-cold saline. Liver was blot dried,
weighed and a 10% homogenate was prepared with ice cold
potassium chloride (150 mM) using a homogenizer (Yamato
LSG LH-21, Japan). The homogenate was used for the estima-
tion of catalase (Miao, 1994), glutathione S-transferase (Jako-
by, 1985) and lipid peroxidation (Konings and Driver, 1979).
Amount of antioxidant enzyme was expressed as units/mg of
tissue.
3.5. In vivo cytotoxic activity in DLA inoculated mice (solid
tumor model)
3.5.1. Maintenance of cell lines
Dalton‘s lymphoma ascites cell lines (DLA) were maintained
and propagated intraperitoneally by serial transplantation in
adult male Swiss albino mice. Fifteen days after tumor trans-
plantation, the DLA bearing mouse (donor) was taped for
the ascitic ﬂuid collection. The ascitic ﬂuid was drawn with
an 18-gauge needle into a sterile syringe. The drawn ﬂuid
was checked for cell viability by trypan blue dye exclusion test.
Cells were counted using Neubauer chamber. The ascitic ﬂuid
Figure A.1 Structure of compounds.
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was suitably diluted in saline. Around 1 million cells (0.1 ml of
10 · 106 cells suspension) were injected subcutaneously to the
right hind limb of male mice to obtain a solid tumor. Treat-
ment was started from 24 h after tumor inoculation. Cisplatin
was injected on alternate days for 2 days. Compounds were
administered daily for 7 days orally from day 1.
3.5.2. Parameters monitored
 Tumor volume.
 Tumor weight.
3.5.2.1. Tumor volume. The radii of the developing tumors
were measured using Vernier calipers at 3 day intervals for
1 month and the tumor volume was calculated using the for-
mula V = 4/3pab2, where a & b represent the major and minor
diameters, respectively (Natesan et al., 2007).
3.5.2.2. Tumor weight. At the end of the fourth week, animals
were sacriﬁced under anesthesia using diethyl ether; the tumor
was extirpated and weighed (Rajkapoor et al., 2007).
The percentage inhibition was calculated by the formula,
% Inhibition ¼ 1 B=A 100
where A is the average tumor weight of the control group.
B is the average tumor weight of the treated group.
4. Statistical analysis
Data were represented as mean ± SEM. Statistical analysis of
the data was carried out by one way ANOVA (GraphPAD
Prism Vesrion 5.02, Instat Software La Jolla, CA, USA) fol-
lowed by Tukey post hoc test. A value of p< 0.05 was consid-
ered to be signiﬁcant.
5. Results
5.1. In vitro cytotoxicity in MCF-7 cells by MTT assay
To check the cytotoxicity in human cells, the breast adenocar-
cinoma (MCF-7) cells were treated with test compounds. All
three compounds showed signiﬁcant cytotoxicity in MCF7
cells at 72 h of drug incubation. The CTC50 of JST, JST2,
JST13, were found to be 127.46 lM, 83.04 lM, 22.04 lM,
respectively. (Fig. A.2)
5.2. DNA fragmentation
Concentration below the CTC50 was selected to study its effect
on DNA damage to the cancer cells MCF-7. A single clear
band of intact DNA was observed in untreated cells, whereas
a smear of DNA, showing clear damage to the DNA was ob-
served in JST2 and JST13 treated cells at concentrations of 80
and 20 lM respectively (Fig. A.3).
5.3. Change in mean survival time (MST) in EAC inoculated
mice
A drastic fall in MST was observed in EAC inoculated control
mice when compared with the treated EAC mice. In EAC inoc-
ulated control mice ﬁrst mortality was observed on day 12 and
all the animals died by day 18. The MST of EAC control mice
(15.16 days) was signiﬁcantly improved by the cisplatin treat-
ment (34.16 days). The MSTs of JST2 treatment at 100 and
200 mg/kg were found to be 19.87 days and 27.62 days respec-
tively. Similarly JST13 at 100 and 200 mg/kg increased the
MST to 20.12 days and 23 days respectively. Among these only
the JST2 treatment at 200 mg/kg dose signiﬁcantly increased
the MST compared to the control. The% ILS in JST2 at 100
and 200 mg/kg was found to be in a dose dependent manner
31.04 and 82.14. (Table B.1) (Fig. A.4).
Figure A.3 DNA fragmentation studies by agarose gel electro-
phoresis (1%). Lane 1: MCF-7 cells without treatment, Lane II:
MCF-7 cells + JST13 (10 lM), Lane III: MCF-7 cells + JST13
(20 lM), Lane IV: MCF-7 cells + JST (120 lM), Lane V: MCF-7
cells + JST2 (40 lM), Lane VI: MCF-7 cells + JST2 (80 lM).
Figure A.2 In vitro cytotoxic effect of synthesized compounds in
MCF-7 (human breast adenocarcinoma cell) by MTT assay after
72 h of exposure. All the values are expressed as mean ± SEM of
three samples.
412 N. Kumar et al.
Author's personal copy
5.4. Change in body weight in EAC inoculated mice
EAC inoculated mice gained the body weight progressively.
The maximum gain (47%) in tumor weight was observed on
day 15 of tumor inoculation. Cisplatin (CP) administration
on day 1 signiﬁcantly (p< 0.05) reduced the elevated body
weight on every monitored day. In drug treated groups only
JST 13 at 200 mg/kg was found effective in reducing tumor
weight on all monitored days. However, at lower dose
(100 mg/kg) both the drugs marginally reduced the elevated
body weight (Fig. A.5).
5.5. Effect of test compounds on haematological parameters and
total protein in EAC inoculated mice
More than two fold increase in WBC count was observed in
EAC inoculated mice when compared to the sham animal.
The CP administration signiﬁcantly (p< 0.05) reversed the
EAC elevated WBC count. However, none of the tested com-
pounds signiﬁcantly (p< 0.05) reduced the WBC counts in
EAC mice. Signiﬁcant fall in the RBC count was also observed
in EAC inoculated mice. Both cisplatin and test compounds
marginally improved the RBC count in EAC inoculated mice.
In drug treated mice a marginal improvement in hemoglobin
levels was observed (Table B.2).
Total protein level was found to be increased in EAC con-
trol mice. After CP administration total protein level was
signiﬁcantly (p< 0.05) reversed. JST2 at 200 mg/kg was found
to be most effective in total protein level among the test drugs
(Table B.3).
5.6. Effect of test compounds on liver antioxidant enzymes in
EAC inoculated mice
The level of lipid peroxidation was signiﬁcantly increased
(p< 0.05) in the EAC control group as compared to the nor-
mal group (Fig. A.6). After the administration of different
doses of JST2 and JST13 (100 mg/kg and 200 mg/kg) in
EAC treated mice, the lipid peroxidation decreased as com-
pared to the control (p< 0.05) except for JST2 at 100 mg/
kg. Tumor inoculation of EAC drastically increased GST level
in the control group as compared to sham from 37.47 to
86.06 lmol of CDNB-GSH formed/min/mg of tissue
(Fig. A.6). CAT level was reduced in the control but it was in-
creased in the drug treated group in a dose dependent manner.
As compared to the control, both the molecules viz JST2 and
JST13 at 200 mg/kg increased the CAT level by 54.68% and
70.47%, respectively (Fig. A.6).
5.7. Effect of test compounds against DLA induced solid tumor
volume in mice
At the end of the fourth week, signiﬁcant development of solid
tumors was observed in all the mice that were inoculated with
DLA cells, which were quantiﬁed by increased tumor volume.
Treatment with CP 3.5 mg/kg at a single dose on day 1 signif-
icantly reduced (95.96%) the tumor volume. JST13 at 200 mg/
kg and 100 mg/kg and JST2 at 200 mg/kg reduced the solid tu-
mor volume signiﬁcantly (p< 0.05) at the end of fourth week.
JST2 at 200 mg/kg inhibited the tumor growth by 81.31%
whereas JST13 at 200 mg/kg reduced the tumor growth by
75.50% (Fig. A.7).
Table B.1 Effect of synthesized compounds on mean survival
time in EAC inoculated mice.
Treatment Dose MST (days) % IMLS
Control (n= 6) 2% Acacia 15.16 ± 0.87 ––
Cisplatin (n= 6) 3.5 34.16 ± 5a 125.27 ± 23
JST 13 (n= 8) 100 20.12 ± 0.89 32.69 ± 5.9
JST 13 (n= 8) 200 23 ± 0.8 51.64 ± 5.28
JST 2 (n= 8) 100 19.87 ± 0.23 31.04 ± 1.39
JST 2 (n= 8) 200 27.62 ± 3.94a 82.14 ± 25.99
All the values are mean ± SEM of indicated No. of mice.
a p< 0.05 compared to control.
Figure A.4 Survival study of synthesized compounds. Where
n= 6 for control and cisplatin; n= 8 for remaining treatment.
Figure A.5 Effect of synthesized compounds on body weight
changes in EAC inoculated mice. All the values are mean ± SEM
of indicated No. of mice, ap< 0.05 compared to control.
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5.8. Effect of test compounds against DLA induced solid tumor
weight in mice
JST2 and JST13 were found signiﬁcantly (p< 0.05) effective
in reducing the tumor weight at end of fourth week. In all
the groups of drug treated mice signiﬁcant (p< 0.05) reduc-
tion in tumor weight was observed as compared to the vehicle
treated group. Both compounds were found more effective at
Table B.2 Effect of synthesized compounds on haematological parameters in EAC inoculated mice.
Group (n= 4) Dose (mg/kg) WBC (103 cells/mm3) RBC (millions/mm3) Hemoglobin (g%)
Sham – 6.25 ± 0.46 3.38 ± 0.22 17.35 ± 1.02
Control 2% Acacia 18.11 ± 1.54a 2.45 ± 0.40 11 ± 1.68a
Cisplatin 3.5 5.57 ± 1.26b 3.40 ± 0.19 14.15 ± 0.99
JST13 100 16.86 ± 0.48 2.52 ± 0.48 13.7 ± 0.78
JST13 200 13.34 ± 1.58 2.89 ± 0.10 14.15 ± 0.39
JST2 100 15.4 ± 1.32 2.48 ± 0.13 11.7 ± 0.67
JST2 200 14.32 ± 1.25 2.92 ± 0.32 13.45 ± 0.52
All the values are mean ± SEM of four samples.
a p< 0.05 compared to sham.
b p< 0.05 compared to control.
Table B.3 Effect of synthesized compound on total protein
level in serum of EAC inoculated mice.
Group
(n = 4)
Dose
(mg/kg)
Total protein
(g/dl)
% Increase
Control – 6.65 ± 0.30 –
Control 2% Acacia 12.85 ± 0.51a –
Cisplatin 3.5 7.22 ± 0.78b 43.77 ± 6.05
JST13 100 6.52 ± 0.29b 49.22 ± 2.27
JST13 200 5.65 ± 0.60b 56.03 ± 4.7
JST2 100 7.22 ± 0.65b 43.13 ± 4.08
JST2 200 4.6 ± 0.61b 64.20 ± 4.76
All the values are mean ± SEM of four samples.
a p< 0.05 compared to sham.
b p< 0.05 compared to control.
Figure A.6 Effect of test compounds on liver antioxidant
enzymes. All the values are mean ± SEM of four samples,
ap< 0.05 compared to sham; bp< 0.05 compared to control.
All the values are mean ± SEM of three mice, ap< 0.05
compared to control.
Figure A.7 Effect of synthesized compounds against DLA
induced solid tumor volume. All the values are mean ± SEM of
six mice.
Figure A.8 Effect of synthesized compounds against DLA
induced solid tumor weight. All the values are mean ± SEM of
six mice.
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higher dose (200 mg/kg) as compared to lower dose (100 mg/
kg). The standard drug CP was found to be very effective in
reducing the tumor weight by 85.11%. However, between the
four treatments, the JST2 at 200 mg/kg was found to be the
most effective treatment in reducing the tumor weight by
60%. The JST13 at 100 mg/kg was found to be the least
effective agent in reducing the tumor weight by 36.69%
(Fig. A.8).
6. Discussion
Farnesyl transferase inhibitors have emerged as a novel class
of anti-cancer agents (Brunner et al., 2003). Tipifarnib, a 3-
aryl-2-quinolone derivative acts as an anticancer agent by sim-
ilar mechanism (inhibiting farnesyl transferase) and is cur-
rently under clinical trials. Assuming that 2-quinolone
analogs are powerful inhibitors of farnesyl transferase (Li
et al., 2005), and a novel class of anticancer drugs, a series
of 2-quinolone analogs were synthesized in our lab. Some of
them are already reported to have anticancer activity in our
earlier study (Kumar et al., 2012). But the study was lacking
the elucidation of in vitro and in vivo antitumor activities of
three compounds (JST, JST2 and JST13). These three com-
pounds were screened for in vitro cytotoxicity, and selected
compounds were further explored for anticancer activity using
tumor bearing mice. Signiﬁcant cytotoxicity was observed in
JST2 and JST13 treated samples and CTC50 values for these
compounds were found at 83.04 lM and 22.04 lM, respec-
tively. Concentrations below the CTC50 for both the com-
pounds were used to check the effect on DNA. JST2 and
JST13 showed clear damage to the DNA, which conﬁrms their
ability to kill cancer cells. Previous studies support our present
ﬁnding and reveal that quinolone derivatives are effective
against a wide range of cancer cells (Joseph et al., 2002; Kumar
et al., 2012). In the present study cell death was assessed at
72 h, which also supports their anti-proliferative activity.
Quinolone analog inhibits tubulin polymerization and induces
apoptosis via Cdk1-involved signaling pathways (Chen et al.,
2007). Further it has been reported that the 2-phenyl-4-quino-
lone analog causes cell cycle arrest at G2/M phase, and a sub-
sequent apoptosis (Chen et al., 2007). Hence a similar
mechanism could be possible here, because all of our test com-
pounds possess quinolone as the basic moiety, though experi-
mental conﬁrmation is still required to correlate this point.
In vivo results obtained indicate the possible therapeutic po-
tential of test compounds. Ehrlich tumor cells are hastily grow-
ing cells with the ability to grow in almost all strains of mice
(Segura et al., 2000). Implantation of the tumor cells induces
a local inﬂammatory reaction followed by a series of responses
like increasing vascular permeability, an intense edema forma-
tion, cellular migration, and results in a progressive ascitic
ﬂuid formation (Fecchio et al., 1990). The ascitic ﬂuid is vital
for tumor growth and it is a nutritional source for tumor cells
(Shimizu et al., 2004). Drug treatment on 1st, 3rd, 5th, 7th,
9th, 11th, and 13th day of inoculation marginally reduced
the tumor weight in EAC inoculated mice. However, JST13
at 200 mg/kg was found most effective in reducing the tumor
weight. Interestingly on day 5 none of the drugs were found
effective in reducing the tumor weight/development.
The reliable criterion for judging the antitumor activity of
any molecule is the prolongation of life span even for human
and for tumor inoculated mice (Gupta et al., 2004). Usually
in untreated mice, EAC inoculation causes 100% mortality
within 18 days, and our present data support this fact. An
enhancement of life span by 25% or more over that of the con-
trol was considered as effective antitumor response (Hazra
et al., 2002). Treatment with JST2 and JST13 also delayed
the onset of mortality and increased the life span of EAC inoc-
ulated mice by 82.14% and 51.64%, respectively. Reduced tu-
mor progression and increased life span in tumor bearing mice
support the antitumor activity of JST2 and JST13. However,
JST13 at 200 mg/kg was found the most effective in reducing
the tumor development and progression. Incidence of EAC in-
duced anemia is usually observed in mice on the 14th day of
tumor transplantation (Price and Greenﬁeld, 1958). In the
present study signiﬁcant reduction in hemoglobin and RBC
was observed in the EAC vehicle treated mice. However mice
treated with test compounds showed only marginal improve-
ment in hemoglobin levels. Similarly no signiﬁcant improve-
ment in the RBC and WBC count was observed in mice
treated with test compounds. Total protein level was found
to be increased in the EAC vehicle treated mice. The protein
levels in serum were elevated in EAC control animals. Treat-
ment with the test compounds signiﬁcantly reversed the rise.
A similar ﬁnding was reported on EAC cells using a plant ex-
tract (Rajkapoor et al., 2004).
Correlation between free radical generation and cancer
development is well documented. Oxidative/electrophilic stress
is generally perceived as one of the major causes of carcinoge-
nicity, and antioxidants are considered as effective against can-
cer development. Excessive free radical generation in oxidative
stress causes damages in macromolecules such as lipids, pro-
teins and carbohydrates (Fenninger and Mider, 1954). The lip-
ids undergo peroxidation at the primary site and the products
of lipid peroxidation generate more free radicals, which mi-
grate along with circulation to the other sites (Yagi, 1991).
Endogenous antioxidant systems such as glutathione and en-
zymes like catalase and superoxide dismutase, play an impor-
tant role in preventing and inactivating them (Sinclair et al.,
1990). For examples, decreased catalase (Sun et al., 1989)
and enhanced malondialdehyde (MDA) levels are documented
in carcinogenesis. (Daniela et al., 2006). Many tumor cells are
also noted to have pro-oxidant status and promote generalized
oxidative stress (Sun, 1990). In the present study a drastic fall
in liver catalase levels and elevation in MDA was observed in
EAC inoculated mice which supports the role of oxidative
stress in cancer progression. Antioxidant molecules such as
sesamol (Kaur and Saini, 2000), dehydrozingerone (Ruby
et al., 1995), curcumin (Mosley et al., 2007) etc. are known
to have protective effects on oxidative stress and cancer
(Jiau-Jian and Larry, 1997). Antioxidants protective role in
cancer through the differential regulation of transcriptional
activator activities and the redox modulation of gene expres-
sion is well documented (Storz et al., 1990). We have observed
that both the compounds enhance catalase levels in EAC inoc-
ulated mice, which support the endogenous antioxidant de-
fense mechanism. Signiﬁcant reduction in lipid peroxidation
was also observed in tumor bearing mice treated with the test
compound. Hence the observed antitumor activity may be due
to in vivo antioxidant properties of JST2 and JST13.
The Dalton’s lymphoma transplanted mice were used to as-
sess the effect of the test compound on solid tumors. In DLA-
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tumor-bearing mice, a regular rapid increase in tumor volume
was observed starting from day 6. Both the studied compounds
signiﬁcantly reduced the tumor size and tumor weight on the
4th week of tumor implantation. Treatment with standard drug
(cisplatin 3.5 mg/kg) at two doses on day 1 and 2 signiﬁcantly
reduced the tumor volume and tumor size. Mice treated with
JST13 at both the doses (200 mg/kg and 100 mg/kg) showed
a signiﬁcant reduction in development. However, JST2 was
found signiﬁcantly effective only at a higher dose (200 mg/
kg), though there was a marginal reduction at a lower dose also.
7. Conclusion
Present study shows that JST2 and JST13 reduce Ehrlich tumor
progression in mice. However efﬁcacy was more prominent
against Dalton’s lymphoma. The exact mechanism responsible
for their antitumor activity may be due to its ability to damage
the DNA of cancer cells, which have to be studied further in de-
tail. There is possibility of multiple mechanisms playing in the
anticancer activities of these compounds. As discussed earlier
2-quinolone analogs inhibit farnesyl transferase, thus retards
further growth by inhibiting theRasmediated pathway and they
also cause apoptosis byDNA damage. Hence these mechanisms
cannot be ignored. Furthermore in EAC models elevated cata-
lase levels and reduced MDA were observed in drug treated
mice. Hence elevated catalase levels and reduced lipid peroxida-
tionmay have contributed to the antitumor activity of JST2 and
JST13. By this study we can conclude that 2-quinolone deriva-
tives JST2 and JST13 are active against both EAC and DLA
models.More prominent activity was observedwith the solid tu-
mor model.
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